Optimized antiretroviral therapy: The role of therapeutic drug monitoring and pharmacogenomics

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 1, 2003, Pages 75-81

  van Heeswijk, Rolf P G ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

HIV; Inhibitory quotient; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESPONSE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; NONHUMAN; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

EID: 2942530951     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.1.75     Document Type: Review

References (53)

1. Lebergeber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353, 863-868 (1999).
2. Wit FWNM, Van Leeuwen R, Weverling GJ et al. Outcomes and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type-1-infected persons. J. Infect. Dis. 179, 790-798 (1999).
3. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87 (1999).
4. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21-30 (2000).
5. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385-394 (2002).
6. Molla A, Korneyeva M, Gao Q et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 124, 1039-1050 (1996).
7. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retrovirus 18, 825-834 (2002).
8. Back D, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1), S5-S37 (2002).
9. Piscitelli SC. The role of therapeutic drfug monitoring in the management of HIV-infected patients. Curr. Infect. Dis. Rep. 4, 353-358 (2002).
10. Burger D, Hugen P, Droste J et al. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001) (Abstract 30).
11. Fletcher CV, Anderson PL, Kakuda TN et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16, 551-560 (2002).
12. Dieleman JP, van Rossum AM, Stricker BC et al. Persistant leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. AIDS 32, 135-142 (2003).
13. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
14. Clevenbergh P, Garaffo R, Durant J et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS 16, 2311-2315 (2002).
15. Heeswijk van RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther. Drug Monit. 24, 323-331 (2002).
16. Sadler BM, Gillotin C, Lou C et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45, 30-37 (2001).
17. Drusano GL, Bilello JA, Preston SL et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacokinetic variable. J. Infect. Dis. 183, 1126-1129 (2001).
18. Schulman N, Zolopa A, Havlir D et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46, 3907-3916 (2002).
19. Fletcher CV, Anderson PL, Hoody D et al. A composite concentration index to assess antiretroviral regimen potency. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 150).
20. Aarnoutse RE, Verweij-van Wissen CPWGM, Underberg WJM et al. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. J. Chromatograph B. 764, 363-384 (2001).
21. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents Chemother. 46, 884-886 (2002).
22. Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47, 350-359 (2003).
23. Acosta EP, King JR. Methods of integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin. Infect. Dis. 36, 373-377 (2003).
24. 50) as predictor of virological response. AIDS 17, 262-264 (2003).
25. Ellner PD, Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246, 1575-1578 (1981).
26. Piliero PJ. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS 16, 799-800 (2002).
27. Montaner J, Hill A, Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 357, 1438-1440 (2001).
28. Marcelin AG, Lamotte C, Delaugerre C et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in hum immunodeficiency virus Type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47, 594-600 (2003).
29. Broder S, Subramanian G, Venter JC. The Human Genome. In: Pharmacogenomics: The Search for Individualized Therapies. Licinio J, Wong ML (Eds). Wiley-VCH Verlag GmbH, Weinheim, Germany (2002).
30. Telenti A, Aubert V, Spertini F et al. Individualizing HIV treatment - pharmacogenetics and immunogenetics. Lancet 359, 722-723 (2002).
31. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277, 959-965 (1997).
32. Wit FW, van Rij RP, Weverling GJ et al. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphism do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus Type 1-infected patients. J. Infect. Dis. 186, 1726-1732 (2002).
33. Carrington M, Nelson G, O'Brien SJ. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunology Lett. 79, 131-140 (2001).
34. Miserez AR, Muller PY, Barella L et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-regulated hyperlipoproteinaemia. AIDS 15, 2045-2049 (2001).
35. Mahler B, Alfiveric A, Vilar FJ et al. TNF-α promotor region gene polymorphism in HIV-positive patients with lipodystrophy. AIDS 16, 2013-2018 (2002).
36. Nolan D, Moore C, Castley A et al. Tumor necrosis factor-α gene -238G/A promotor polymorphism associated with a more rapid onset of lipodystrphy. AIDS 17, 121-123 (2003).
37. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
38. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersenstivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
39. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multi-drug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36 (2002).
40. Brumme ZL, Dong WWY, Chan KJ et al. Influence of polymorphisms within CX3CR1 and MDR1 genes on initial antiretroviral therapy response. AIDS 17, 201-208 (2003).
41. Meyer UA. Pharmacogenetics and adverse drug reactions. Adv. Drug React. 356, 1667-1671 (2000).
42. Lennard MS, Silas JH, Freestone S et al. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N. Engl. J. Med. 307, 1558-1560 (1982).
43. Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol associated adverse effects. Clin. Pharmacol. Ther. 72, 429-437 (2002).
44. Fellay J, Marzolini C, Greub G et al. Predictive power of P-glycoprotein and CYP2D6 polymorphisms for plasma levels of antiretroviral agents. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract 260).
45. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 14, 237-242 (2000).
46. Hoffmeyer S, Burk O, von Richert O et al. Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000).
47. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphism of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. 43, 285-307 (2003).
48. Johne A, Kopke K, Gerloff T et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594 (2002).
49. Singh K, Saitoh A, Powell C et al. Allelic variants of MDR1 alter pharmacokinetics of nelfinavir resulting in higher drug levels and more rapid decline in plasma in HIV-1 RNA in children. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 100).
50. Maher B, Hoggard PG, Chandler B et al. The effect of ABCB1 (MDR1) polymorphism on the plasma and intracellular pharmacokinetics of indinavir and glucose handling in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 524a).
51. Verstuyft C, Marcellin F, Morgand-Joubert L et al. Impact of MDR1 (C3435T) genetic polymorphism in patients naive treated with HAART including indinavir. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 522).
52. Nasi M, Borghi V, Pinti M et al. MDR-1 genetic polymorphism does not influence the response to antiretroviral therapy with protease inhibitors in drug-naive patients with HIV infection. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, (2003 (Abstract 523).
53. Peterson C, Pun E, Myrand S et al. Allelic variants of MDR1, CYP2C19 and CYP3A5: distribution and associations in patients receiving nelfinavir or efavirenz-containing HAART. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) (Abstract 575).